The forecast of the stock depends on the analyst's view. That being said, the company's earnings and revenue are expected to grow by 16.6% and 10.2% p.a., respectively. The return on equity is forecasted to reach 15.7% in the next 3 years, while the Earnings Per Share might increase by 16.8%.
The highest stock price of Cipla was rupees 1185.25.
Analysts at Motilal Oswal have kept a positive outlook on the stock on the back of respiratory asset build-up for the NA market and robust brand franchise in DF and inorganic growth given the surplus cash of INR 75 Billion as of Q3 FY 24. Analysts have retained a 'BUY' opinion on the stock with a target price of 1,600
Cipla is a leading name in the pharmaceutical industry, with a market capitalization of 76,171.42 crores. The EPS is 34.28, and the share capital is worth 161.36 crores. Thus, the company has a solid foundation.
The financial results for the year ended 31st March 2022 are yet to be declared. The final dividend payout date will be mentioned in the financial results. Cipla's last dividend was in July 2022, a final dividend of 5 per share.
Some of the most recent Cipla stock news are as follows –